Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Amprolium is a small molecule coccidiostat primarily used in veterinary medicine, especially for the prevention and treatment of coccidiosis in poultry such as chickens, turkeys, and pheasants[1][7]. It is a quaternized derivative of pyrimidine and acts as a thiamine (vitamin B1) antagonist due to its structural similarity to thiamine[3][5][8]. By competitively inhibiting thiamine uptake via blockade of the thiamine transporter in *Eimeria* species (the causative agents of coccidiosis), it disrupts carbohydrate synthesis essential for parasite survival[3][5][8]. Amprolium is effective against several *Eimeria* species including *E. tenella*, *E. necatrix*, and *E. acervulina*. It has a wide margin of safety in poultry but can induce thiamine deficiency at high doses or with prolonged use[3][6]. The drug is rapidly eliminated via the kidneys and does not require an egg withdrawal period when used according to labeling[7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on amprolium.